BioSpace News Archive

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2022, after the close of market on Wednesday, July 27, 2022.

Addex Therapeutics Ltd announced that it has completed an equity financing transaction entered into on July 22, 2022 with Armistice Master Fund Ltd., a healthcare-focused institutional investor, pursuant to which the Company sold 4,500,000 shares in the form of 750,000 American Depositary Shares at a gross purchase price of $1.70 per ADS, which is equivalent to CHF 0.27 per share, in an offering registered with the US SEC.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), today announced that it will report its financial results for the second quarter ended June 30, 2022, and provide an update on recent business highlights, on August 4, 2022.

Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), today announced that the first patient has been dosed in a Phase 1 study of an investigational candidate resulting from the collaboration between Sutro and Merck, known as MSD outside the United States and Canada, for the development of a novel cytokine derivative therapeutic for the treatment of cancer.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2022 second quarter on Tuesday, August 9, 2022, after the market close.

Stryker (NYSE:SYK) reported operating results for the second quarter of 2022.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2022.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company will present at the Canaccord Genuity 42nd Annual Global Growth Conference on August 10, 2022 beginning at 8:00 AM ET.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), today announced that members of the management team will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference at the InterContinental Boston Hotel.

Rapid Medical, a leading developer of advanced neurovascular devices, announces FDA 510(k) clearance for TIGERTRIEVER™13 for large vessel occlusions at the 2022 Society of NeuroInterventional Surgery’s (SNIS) 19th Annual Meeting in Toronto.